InfectRisk

Respiratory illness in Japan

The three major respiratory pathogens side by side (influenza, COVID-19 and RSV) based on WHO FluNet weekly aggregate of NIID sentinel laboratory data.

Influenza: Moderate

Moderate

Yes, moderately. Flu activity in Japan is currently moderate and rising (as of 16 Aug 2026).

Data window: Week 33 · Aug 10 – Aug 16 · Source: WHO FluNet (weekly) · Update overdue: source publishing late

Get one free alert when the wave turns in Japan

We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy

View the last 8 weeks

In week 33 of 2026, Influenza activity in Japan is classified as moderate.

The reported value is 243% higher than in week 32.

Across the last 8 reported weeks the highest reading was week 33; the level was low in 7 of them.

The last 8 reported weeks

WeekRelativeLevelvs prior week
Week 33100Moderate+243%
Week 3229Low+106%
Week 3114Low+145%
Week 306Low+53%
Week 294Low−13%
Week 284Low+319%
Week 271Low−67%
Week 263Low

Relative means the highest of these weekly values is set to 100. Exact incidence rates are in the app.

Is flu going around right now?

Know when it affects you.

This page shows your country. The app shows you.

  • Exact numbers and incidence rates, not just low, moderate, high
  • Your personal risk by age and region
  • A push alert when the wave tips in your region
  • 35 countries and a home-screen widget
Download on the

Current activity

12-week trend · Flu and RSV · Each curve on its own scale · Relative development
Week 22Week 25Week 28Week 30Week 33
Influenza
RSV
  • InfluenzaModerate
    Trend: rising · Week 33
  • RSVLow
    Trend: falling · Week 33

Situation by pathogen

Current activity in Japan: Influenza moderate, RSV low. This reads the weekly WHO FluNet publications, most recently Week 33.

InfluenzaDetails

In week 33 of 2026, activity of influenza (seasonal flu) in Japan is moderate. The trend, derived from clinical surveillance, is rising. A clear upward movement has emerged over the past few weeks.

RSVDetails

In week 33 of 2026, activity of respiratory syncytial virus (RSV) in Japan is low. The trend, derived from clinical surveillance, is falling. Over a four-week comparison, a clear decline is visible.

Data, context and methodology

The current picture for Japan is built on WHO FluNet, the World Health Organization's global platform for influenza surveillance. the National Institute of Infectious Diseases (NIID) reports weekly sentinel laboratory results to FluNet, which we translate into a consultation-equivalent signal.

WHO FluNet

FluNet is the WHO's weekly global influenza surveillance database. National influenza centres and reference laboratories, for Japan this is the National Institute of Infectious Diseases (NIID), submit the number of respiratory specimens tested and the number positive for influenza and, where available, RSV. Using FluNet ensures a consistent, internationally comparable data source for countries without a European-style sentinel consultation system.

Positivity-based signal

Unlike ECDC ERVISS, FluNet does not carry outpatient consultation rates. Our headline signal is therefore derived from the weekly lab positivity rate (percent of tested specimens that are positive), multiplied by a pathogen-specific scaling factor (80 for influenza and 50 for RSV) to approximate a consultation-equivalent incidence. COVID-19 is not available via FluNet and is therefore not shown for these countries.

Why this source

FluNet is the only weekly, comparable dataset covering many non-European countries. Positivity is relatively insensitive to changes in overall testing volume, which makes it a reasonable proxy for underlying transmission pressure even when the denominator fluctuates. We apply a SENTINEL-only filter where appropriate to reduce noise from non-sentinel reporting streams.

Qualitative classification

The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The positivity × scaling-factor product is mapped to the same consultation-equivalent scale we use elsewhere so results stay comparable across regions. Data refreshes weekly when WHO publishes the latest FluNet update.

Source and seasonal pattern by pathogen

Influenza
The classification is based on the WHO FluNet aggregate of sentinel laboratory data from Japan's National Institute of Infectious Diseases (NIID). Seasonally, infection waves in Japan typically peak between January and February; activity is usually markedly lower during the summer months.
COVID-19
The classification is based on the WHO FluNet aggregate of sentinel laboratory data from Japan's National Institute of Infectious Diseases (NIID), used as a proxy for respiratory virus activity. Seasonally, infection waves in Japan typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
RSV
The classification is based on the WHO FluNet aggregate of sentinel laboratory data from Japan's National Institute of Infectious Diseases (NIID), which includes RSV positivity indicators. Seasonally, infection waves in Japan typically peak between December and February; activity is usually markedly lower in spring and summer.

Frequently asked questions

How is overall respiratory-illness activity tracked in Japan?

NIID aggregates weekly reports from its national sentinel networks for influenza and RSV, together with virological testing at prefectural laboratories. Published in the Infectious Agents Surveillance Report (IASR), these indicators describe the burden carried by primary care and paediatric services. The same data is transmitted to WHO FluNet for international comparison.

Why isn't COVID-19 tracked here alongside flu and RSV?

WHO FluNet, the international platform that aggregates Japan's sentinel data, covers influenza and RSV, not SARS-CoV-2. COVID-19 has its own surveillance streams, including genomic and wastewater systems. That is why data pages built on FluNet for Japan, India, and China focus on flu and RSV only. COVID-19 monitoring in Japan continues via other NIID and Ministry of Health channels.

Why does respiratory illness peak in Japanese winters?

Japan's winter respiratory peak reflects the usual mix of cold, dry indoor air, reduced ventilation, and dense indoor contact in workplaces and schools. Influenza drives the sharp January–February spike, while RSV may contribute either earlier or during winter depending on the year. The combined curve is one of the most sharply defined in the Northern Hemisphere.

How does Japan compare internationally?

Japan's flu peak typically arrives earlier and is more tightly concentrated in January–February than European or US peaks. RSV timing has been less stable since 2021. Because NIID feeds WHO FluNet, Japan's trajectory can be overlaid directly with other Western Pacific countries (South Korea, Australia, China) and with Northern-Hemisphere countries elsewhere.

How does NIID classify respiratory-illness activity?

NIID uses qualitative tiers (baseline, caution, warning, epidemic) for influenza, with separate activity classifications for RSV anchored to historical reference ranges. These tiers describe whether current sentinel reporting rates are ordinary, elevated, or unusually intense. They intentionally avoid implying precision that sentinel-based surveillance cannot support.

More situation reports

WHO FluNetWHO FluNet ChartsUpdated: Sep 1, 2026, 10:15
Published by Dominik Martin · Software engineer and data aggregator· Methodology last reviewed: 07 May 2026· Methodology version 1.2

Data last refreshed: Sep 1, 2026, 10:15. Update cadence: weekly.

This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.

About this page

Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.

Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.

Methodology enquiries: press@infectrisk.com

About this site and its author